The 100 references in paper R. Samsonov B., Z. Radzhabova A., Yu. Cheburkin V., V. Klyuge A., E. Tkachenko V., A. Malek V., Р. Самсонов Б., З. Раджабова А., Ю. Чебуркин В., В. Клюге А., Е. Ткаченко В., А. Малек В. (2017) “ЭПИГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ РЕГУЛЯЦИИ ГЕННОЙ ЭКСПРЕССИИ В РАЗВИТИИ ПЛОСКОКЛЕТОЧНОГО РАКА ГОЛОВЫ И ШЕИ: ТЕРАПЕВТИЧЕСКИЕ ПЕРСПЕКТИВЫ // EPIGENETIC REGULATION OF GENE EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: THERAPEUTIC PERSPECTIVES” / spz:neicon:ogsh:y:2016:i:4:p:35-44

1
Суконко О.Г., Красный С.А. Алгоритмы диагностики и лечения злокачественных новообразований. Под ред. О.Г. Суконко, С.А. Красного. Минск, 2012. С. 13–30. [Sukonko O.G., Krasnyy S.A. Algorithms of diagnostics and treatment of malignant neoplasms. Eds. by O.G. Sukonko, S.A. Krasnyy. Minsk, 2012. Pp. 13–30. (In Russ.)].
(check this in PDF content)
2
Вельшер Л.З., Матякин Е.Г., Дудицкая Т.К., Поляков Б.И. Онкология. М.: ГЭОТАРМедиа, 2009. 512 с. [Vel’sher L.Z., Matyakin E.G., Duditskaya T.K., Polyakov B.I. Oncology. Moscow: GEOTAR-Media, 2009. 512 p. (In Russ.)].
(check this in PDF content)
3
Bychkov V.A., Nikitina E.G., Ibragimova M.K. et al. Comprehensive meta-analytical summary on human papillomavirus association with head and neck cancer. Exp Oncol 2016;38(2):68–72.
(check this in PDF content)
4
Jalouli J., Jalouli M.M., Sapkota D. et al. Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res 2012:32(2):571–80.
(check this in PDF content)
5
Кропотов М.А. Общие принципы лечения больных первичным раком головы и шеи. Практическая онкология 2003;4(1):1–8. [Kropotov M.A. General principles of treatment of patients with primary cancer of the head and neck. Prakticheskaya onkologiya = Practical Oncology 2003;4(1): 1–8. (In Russ.)].
(check this in PDF content)
6
Алферов В.С. Органосохраняющие методы лечения рака гортани. М., 1993. 350 c. [Alferov V.S. Organ-preserving methods of treatment of cancer of the larynx. Moscow, 1993. 350 p. (In Russ.)].
(check this in PDF content)
7
Mудунов А.М. Сравнительная оценка эффективности неоадъювантной химиотерапии в комплексном и комбинированном лечении плоскоклеточного рака слизистой оболочки полости рта и ротоглотки. Дис. ... канд. мед. наук. М., 2002. 25 с. [Mudunov A.M. Comparative evaluation of neoadjuvant chemotherapy in the complex and combined treatment of squamous cell carcinoma of the mucosa of the oral cavity and oropharynx. Thesis ... of candidate of medicine. Moscow, 2002. 25 p. (In Russ.)].
(check this in PDF content)
8
Практические рекомендации по лекарственному лечению опухолей головы и шеи. Злокачественные опухоли 2015;(4s):47–54. [Practical recommendations for drug treatment of tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2015;(4s):47–54. (In Russ.)].
(check this in PDF content)
9
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Eds. by: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, 2016. (In Russ.)].
(check this in PDF content)
10
Ванюшин Б.Ф. Эпигенетика сегодня и завтра. Вавиловский журнал генетики и селекции 2013;17(4/2):805–32. [Vanyushin B.F. Epigenetics today and tomorrow. Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Plant Breeding 2013;17(4/2):805–32. (In Russ.)].
(check this in PDF content)
11
Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148–59. DOI: 10.1056/NEJMra072067.
(check this in PDF content)
12
Fan C.Y. Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep 2004;6(2):152–61.
(check this in PDF content)
13
Bakhtiar S.M., Ali A., Barh D. Epigenetics in head and neck cancer. Methods Mol Biol 2015;1238:751–69. DOI: 10.1007/978-1-4939-1804-1_39.
(check this in PDF content)
14
Demokan S., Dalay N. Role of DNA methylation in head and neck cancer. Clin Epigenetics 2011;2(2):123–50. DOI: 10.1007/s13148-011-0045-3.
(check this in PDF content)
15
Shridhar K., Walia G.K., Aggarwal A. et al. DNA methylation markers for oral pre-cancer progression: A critical review. Oral Oncol 2016;53:1–9. DOI: 10.1016/j.oraloncology.2015.11.012.
(check this in PDF content)
16
Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420–32.
(check this in PDF content)
17
Chen Y.W., Kao S.Y., Wang H.J., Yang M.H. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Cancer 2013;119(24):4259-67. DOI: 10.1002/cncr.28356.
(check this in PDF content)
18
URL: http:// www.mirbase.org/.
(check this in PDF content)
19
Gunaratne P.H., Creighton C.J., Watson M., Tennakoon J.B. Large-scale integration of microRNA and gene expression data for identification of enriched microRNAmRNA associations in biological systems. Methods Mol Biol 2010;667:297–315. DOI: 10.1007/978-1-60761-811-9_20.
(check this in PDF content)
20
Gulyaeva L.F., Kushlinskiy N.E. Regulatory mechanisms of microRNA expression. J Transl Med 2016;14(1):143. DOI: 10.1186/s12967-016-0893-x.
(check this in PDF content)
21
Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu Rev Pathol 2014;9:287–314. DOI: 10.1146/annurev-pathol-012513-104715.
(check this in PDF content)
22
Courthod G., Franco P., Palermo L. et al. The role of microRNA in head and neck cancer: current knowledge and perspectives. Molecules 2014;19(5):5704–16. DOI: 10.3390/molecules19055704.
(check this in PDF content)
23
John K., Wu J., Lee B.W., Farah C.S. MicroRNAs in Head and Neck Cancer. Int J Dent 2013;2013:650218. DOI: 10.1155/2013/650218.
(check this in PDF content)
24
Choi J.D., Lee J.S. Interplay between Epigenetics and Genetics in Cancer. Genomics Inform 2013;11(4):164–73. DOI: 10.5808/GI.2013.11.4.164.
(check this in PDF content)
25
Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013;153(1):38–55.
(check this in PDF content)
26
Chuang J.C., Jones P.A. Epigenetics and microRNAs. Pediatr Res 2007;61(5 Pt 2):24R–29R.
(check this in PDF content)
27
Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010;31(1):27–36.
(check this in PDF content)
28
Baylin S.B., Jones P.A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8(9):a019505. DOI: 10.1101/cshperspect.a019505.
(check this in PDF content)
29
Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5(1):37–50.
(check this in PDF content)
30
Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10(5):295–304. DOI: 10.1038/nrg2540.
(check this in PDF content)
31
Nan X., Ng H.H., Johnson C.A. et al. Transcriptional repression by the methyl-CpGbinding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393(6683):386–9.
(check this in PDF content)
32
Fuks F., Hurd P.J., Wolf D. et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278(6):4035–40.
(check this in PDF content)
33
Fuks F., Burgers W.A., Brehm A. et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24(1):88–91.
(check this in PDF content)
34
Sato F., Tsuchiya S. Meltzer S.J., Shimizu K. MicroRNAs and epigenetics. FEBS J 2011;278(10):1598–609. DOI: 10.1111/j.1742-4658.2011.08089.x.
(check this in PDF content)
35
Wu L., Mao L., Qi Y. Roles of dicer-like and argonaute proteins in TAS-derived small interfering RNA-triggered DNA methylation. Plant Physiol 2012;160(2):990–9. DOI: 10.1104/pp.112.200279.
(check this in PDF content)
36
Wu L., Zhou H., Zhang Q. et al. DNA methylation mediated by a microRNA pathway. Mol Cell 2010;38(3):465–75. DOI: 10.1016/j.molcel.2010.03.008.
(check this in PDF content)
37
Wong T.S., Gao W., Chan J.Y. Interactions between E-cadherin and microRNA deregulation in head and neck cancers: the potential interplay. Biomed Res Int 2014;2014:126038. DOI: 10.1155/2014/126038.
(check this in PDF content)
38
Entrevan M., Schuettengruber B., Cavalli G. Regulation of Genome Architecture and Function by Polycomb Proteins. Trends Cell Biol 2016;26(7):511–25. DOI: 10.1016/j.tcb.2016.04.009.
(check this in PDF content)
39
Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009;10(10):697–708. DOI: 10.1038/nrm2763.
(check this in PDF content)
40
Li X., Lin Y., Yang X. et al. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2016;473(4):913–9. DOI: 10.1016/j.bbrc.2016.03.150.
(check this in PDF content)
41
Sander S., Bullinger L., Klapproth K. et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112(10):4202–12. DOI: 10.1182/blood-2008-03-147645.
(check this in PDF content)
42
Varambally S., Cao Q., Mani R.S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322(5908):1695–9. DOI: 10.1126/science.1165395.
(check this in PDF content)
43
Siddique H.R., Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012;30(3):372–8. DOI: 10.1002/stem.1035.
(check this in PDF content)
44
Lundberg M., Renkonen S., Haglund C. et al. Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas. Acta Otolaryngol 2016;136(5):501–5. DOI: 10.3109/00016489.2015.1122227.
(check this in PDF content)
45
Hauser B., Zhao Y., Pang X. et al. Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS One 2015;10(3):e0116321. DOI: 10.1371/journal.pone.0116321.
(check this in PDF content)
46
Yu X., Jiang X., Li H. et al. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev 2014;23(6):576–85. DOI: 10.1089/scd.2013.0308.
(check this in PDF content)
47
Swierczynski S., Klieser E., Illig R. et al. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015;15(5):651–64. DOI: 10.1517/14712598.2015.1025047.
(check this in PDF content)
48
Le J.M., Squarize C.H., Castilho R.M. Histone modifications: Targeting head and neck cancer stem cells. World J Stem Cells 2014;6(5):511–25. DOI: 10.4252/wjsc.v6.i5.511.
(check this in PDF content)
49
Cho J.H., Dimri M., Dimri G.P. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem 2015;290(16):10555–67. DOI: 10.1074/jbc.M114.624361.
(check this in PDF content)
50
Koumangoye R.B., Andl T., Taubenslag K.J. et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer 2015;14:24. DOI: 10.1186/s12943-014-0284-y.
(check this in PDF content)
51
Taby R., Issa J.P. Cancer epigenetics. CA Cancer J Clin 2010;60(6):376–92. DOI: 10.3322/caac.20085.
(check this in PDF content)
52
Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010;19(5):698–711. DOI: 10.1016/j.devcel.2010.10.005.
(check this in PDF content)
53
Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009;41(1):87–95. DOI: 10.1016/j.biocel.2008.09.005.
(check this in PDF content)
54
Roman-Gomez J., Agirre X., JiménezVelasco A. et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 2009;27(8):1316–22. DOI: 10.1200/JCO.2008.19.3441.
(check this in PDF content)
55
Bandres E., Agirre X., Bitarte N. et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009;125(11):2737–43. DOI: 10.1002/ijc.24638.
(check this in PDF content)
56
Lujambio A., Calin G.A., Villanueva A. et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105(36):13556–61. DOI: 10.1073/pnas.0803055105.
(check this in PDF content)
57
Lehmann U., Hasemeier B., Christgen M. et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008;214(1):17–24.
(check this in PDF content)
58
Zhu D.D., Zhang J., Deng W. et al. Significance of NF-kappaB activation in immortalization of nasopharyngeal epithelial cells. Int J Cancer 2016;138(5):1175–85. DOI: 10.1002/ijc.29850.
(check this in PDF content)
59
He L., He X., Lim L.P. et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447(7148):1130–4.
(check this in PDF content)
60
Chang T.C., Wentzel E.A., Kent O.A. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26(5):745–52.
(check this in PDF content)
61
Lodygin D., Tarasov V., Epanchintsev A. et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7(16):2591–600.
(check this in PDF content)
62
Saito Y., Liang G., Egger G. et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9(6):435–43.
(check this in PDF content)
63
Toyota M., Suzuki H., Sasaki Y. et al. Epigenetic silencing of microRNA-34b/c and Bcell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68(11):4123–32. DOI: 10.1158/0008-5472.CAN-08-0325.
(check this in PDF content)
64
Jia L.F., Wei S.B., Mitchelson K. et al. miR-34a inhibits migration and invasion of tongue squamous cell carcinoma via targeting MMP9 and MMP14. PLoS One 2014;9(9):e108435. DOI: 10.1371/journal.pone.0108435.
(check this in PDF content)
65
Cao X., Pfaff S.L., Gage F.H. A functional study of miR-124 in the developing neural tube. Genes Dev 2007;21(5):531–6.
(check this in PDF content)
66
Cheng Y., Li Y., Nian Y. et al. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 2015;15:306. DOI: 10.1186/s12885-015-1303-0.
(check this in PDF content)
67
Peng X.H., Huang H.R., Lu J. et al. MiR124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer 2014;13:186. DOI: 10.1186/1476-4598-13-186.
(check this in PDF content)
68
Shin K.H., Pucar A., Kim R.H. et al. Identification of senescence-inducing microRNAs in normal human keratinocytes. Int J Oncol 2011;39(5):1205–11. DOI: 10.3892/ijo.2011.1111.
(check this in PDF content)
69
Ando T., Yoshida T., Enomoto S. et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009;124(10):2367–74. DOI: 10.1002/ijc.24219.
(check this in PDF content)
70
Dang J., Bian Y.Q., Sun J.Y. et al. Micro RNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2013;42(4):315–21. DOI: 10.1111/jop.12012.
(check this in PDF content)
71
Kozaki K., Imoto I., Mogi S. et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68(7):2094-105. DOI: 10.1158/0008-5472.CAN-07-5194.
(check this in PDF content)
72
Hezova R., Kovarikova A., Srovnal J. et al. Diagnostic and prognostic potential of miR21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. Diagn Pathol 2015;10:42.
(check this in PDF content)
73
Wellner U., Schubert J., Burk U.C. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11(12):1487–95.
(check this in PDF content)
74
Wiklund E.D., Bramsen J.B., Hulf T. et al. Coordinated epigenetic repression of the miR200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128(6):1327–34. DOI: 10.1002/ijc.25461.
(check this in PDF content)
75
Tamagawa S., Beder L.B., Hotomi M. et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 2014;33(4):879–86. DOI: 10.3892/ijmm.2014.1625.
(check this in PDF content)
76
Bueno M.J.1, Pérez de Castro I., Gómez de Cedrón M. et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL oncogene expression. Cancer Cell 2008;13(6):496–506. DOI: 10.1016/j.ccr.2008.04.018.
(check this in PDF content)
77
Furuta M., Kozaki K.I., Tanaka S. et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31(5):766–76. DOI: 10.1093/carcin/bgp250.
(check this in PDF content)
78
Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269(1):7–17.
(check this in PDF content)
79
Erlich R.B., Rickwood D., Coman W.B. et al. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol 2009;63(3):381–9. DOI: 10.1007/s00280-008-0747-1.
(check this in PDF content)
80
Starkova J., Madzo J., Cario G. et al. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells. Clin Cancer Res 2007;13(6):1726–35.
(check this in PDF content)
81
Cinatl J. Jr, Cinatl J., Driever P.H. et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997;8(10):958–63.
(check this in PDF content)
82
Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25(4):383–97.
(check this in PDF content)
83
Hrebackova J., Hrabeta J., Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 2010;11(3):361–79.
(check this in PDF content)
84
Witt D., Burfeind P., von Hardenberg S. et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis 2013;34(5):1115–24. DOI: 10.1093/carcin/bgt019.
(check this in PDF content)
85
Gan C.P., Hamid S., Hor S.Y. et al. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2012;34(3):344–53. DOI: 10.1002/hed.21734.
(check this in PDF content)
86
Lee S.H., Nam H.J., Kang H.J. et al. Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. Oncol Rep 2015;34(4):2065–71. DOI: 10.3892/or.2015.4145.
(check this in PDF content)
87
Oikawa H., Goh W.W., Lim V.K. et al. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. Neurochem Int 2015;91:62–71. DOI: 10.1016/j.neuint.2015.10.010.
(check this in PDF content)
88
Trécul A., Morceau F., Gaigneaux A. et al. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. Biochem Pharmacol 2014;92(2):299–311. DOI: 10.1016/j.bcp.2014.07.035.
(check this in PDF content)
89
Datta J., Islam M., Dutta S. et al. Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 2016;56:32–9. DOI: 10.1016/j.oraloncology.2016.02.015.
(check this in PDF content)
90
Datta J., Smith A., Lang J.C. et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cɛ. Oncogene 2012;31(36):4045–53. DOI: 10.1038/onc.2011.565.
(check this in PDF content)
91
Piao L., Zhang M., Datta J. et al. Lipidbased nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20(6):1261–9. DOI: 10.1038/mt.2012.67.
(check this in PDF content)
92
Jiang L., Liu X., Kolokythas A. et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010;127(3):505–12. DOI: 10.1002/ijc.25320.
(check this in PDF content)
93
Song T., Zhang X., Wang C. et al. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev 2011;12(5):1307–11.
(check this in PDF content)
94
Liu X., Wang C., Chen Z. et al. Micro RNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011;440(1):23–31. DOI: 10.1042/BJ20111006.
(check this in PDF content)
95
Alhazzazi T.Y., Kamarajan P., Joo N. et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011;117(8):1670–8. DOI: 10.1002/cncr.25676.
(check this in PDF content)
96
Cheng Y., Mai J., Hou T., Ping J. Micro RNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3. Biochem Biophys Res Commun 2016;474(1):57–63. DOI: 10.1016/j.bbrc.2016.04.065.
(check this in PDF content)
97
Sengupta S., Muir J.G., Gibson P.R. Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 2006;21(1 Pt 2): 209–18.
(check this in PDF content)
98
Humphreys K.J., Cobiac L., Le Leu R.K. et al. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013;52(6):459–74. DOI: 10.1002/mc.21879.
(check this in PDF content)
99
Hu S., Liu L., Chang E.B. et al. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol Cancer 2015;14:180. DOI: 10.1186/s12943-015-0450-x.
(check this in PDF content)
100
Chen H.C., Chen G.H., Chen Y.H. et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009;100(6):1002–11. DOI: 10.1038/sj.bjc.6604948.
(check this in PDF content)